NEW YORK, December 2, 2016 /PRNewswire/ --
On Thursday, the NASDAQ Composite and the S&P 500 ended the trading session in red, while the Dow Jones Industrial Average managed to stay in green. Losses were broad based at the close of US markets, which prompted Stock-callers this morning to look at the performances of the following healthcare stocks: NuVasive Inc. (NASDAQ: NUVA), Smith & Nephew PLC (NYSE: SNN), Nxstage Medical Inc. (NASDAQ: NXTM), and Cesca Therapeutics Inc. (NASDAQ: KOOL). You can access our complimentary research reports on these stocks now at:
http://stock-callers.com/registration
NuVasive
On Thursday, shares in San Diego, California headquartered NuVasive Inc. ended the session 2.30% lower at $63.41 with a total volume of 557,012 shares traded. NuVasive's shares gained 8.88% in the previous one month and 20.83% in the past one year. Shares of the Company, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, are trading at a PE ratio of 80.47. The stock is trading 10.03% above its 200-day moving average. Moreover, shares of the Company have a Relative Strength Index (RSI) of 51.60.
On November 30th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock, issuing a target price of $72 per share. Visit us today and download your complete report on NUVA for free at:
http://stock-callers.com/registration/?symbol=NUVA
Smith & Nephew
On Thursday, shares in London, the UK headquartered Smith & Nephew PLC recorded a trading volume of 594,656 shares, which was higher than their three months average volume of 548,950 shares. The stock ended the day 1.40% lower at $28.07. Shares of the Company, which develops, manufactures, markets, and sells medical technology products and services worldwide, are trading at a PE ratio of 35.35. The Company is trading below its 50-day and 200-day moving averages by 6.21% and 13.28%, respectively. Furthermore, Smith & Nephew's shares have an RSI of 40.24. The complimentary research report on SNN can be accessed at:
http://stock-callers.com/registration/?symbol=SNN
Nxstage Medical
Lawrence, Massachusetts headquartered Nxstage Medical Inc.'s stock finished Thursday's session 3.16% lower at $23.94 with a total volume of 424,068 shares traded. Over the last one month and the previous three months, Nxstage Medical's shares have advanced 7.60% and 4.68%, respectively. Furthermore, the stock has gained 18.63% in the past one year. Shares of the Company, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, are trading above its 200-day moving average by 16.62%. Nxstage Medical's stock has an RSI of 42.69. Register for free on Stock-Callers.com and download the PDF research report on NXTM at:
http://stock-callers.com/registration/?symbol=NXTM
Cesca Therapeutics
Rancho Cordova, California headquartered Cesca Therapeutics Inc.'s stock advanced 1.92%, to close the day at $3.19. The stock recorded a trading volume of 44,597 shares. Cesca Therapeutics' shares have surged 11.93% in the previous one month and 678.05% in the past one year. Shares of the Company, which focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine in the US and internationally, are trading 3.79% and 1.69% below its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 51.02. Get free access to your research report on KOOL at:
http://stock-callers.com/registration/?symbol=KOOL
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Advertisement
On Thursday, the NASDAQ Composite and the S&P 500 ended the trading session in red, while the Dow Jones Industrial Average managed to stay in green. Losses were broad based at the close of US markets, which prompted Stock-callers this morning to look at the performances of the following healthcare stocks: NuVasive Inc. (NASDAQ: NUVA), Smith & Nephew PLC (NYSE: SNN), Nxstage Medical Inc. (NASDAQ: NXTM), and Cesca Therapeutics Inc. (NASDAQ: KOOL). You can access our complimentary research reports on these stocks now at:
Advertisement
http://stock-callers.com/registration
NuVasive
On Thursday, shares in San Diego, California headquartered NuVasive Inc. ended the session 2.30% lower at $63.41 with a total volume of 557,012 shares traded. NuVasive's shares gained 8.88% in the previous one month and 20.83% in the past one year. Shares of the Company, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, are trading at a PE ratio of 80.47. The stock is trading 10.03% above its 200-day moving average. Moreover, shares of the Company have a Relative Strength Index (RSI) of 51.60.
On November 30th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock, issuing a target price of $72 per share. Visit us today and download your complete report on NUVA for free at:
http://stock-callers.com/registration/?symbol=NUVA
Smith & Nephew
On Thursday, shares in London, the UK headquartered Smith & Nephew PLC recorded a trading volume of 594,656 shares, which was higher than their three months average volume of 548,950 shares. The stock ended the day 1.40% lower at $28.07. Shares of the Company, which develops, manufactures, markets, and sells medical technology products and services worldwide, are trading at a PE ratio of 35.35. The Company is trading below its 50-day and 200-day moving averages by 6.21% and 13.28%, respectively. Furthermore, Smith & Nephew's shares have an RSI of 40.24. The complimentary research report on SNN can be accessed at:
http://stock-callers.com/registration/?symbol=SNN
Nxstage Medical
Lawrence, Massachusetts headquartered Nxstage Medical Inc.'s stock finished Thursday's session 3.16% lower at $23.94 with a total volume of 424,068 shares traded. Over the last one month and the previous three months, Nxstage Medical's shares have advanced 7.60% and 4.68%, respectively. Furthermore, the stock has gained 18.63% in the past one year. Shares of the Company, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, are trading above its 200-day moving average by 16.62%. Nxstage Medical's stock has an RSI of 42.69. Register for free on Stock-Callers.com and download the PDF research report on NXTM at:
http://stock-callers.com/registration/?symbol=NXTM
Cesca Therapeutics
Rancho Cordova, California headquartered Cesca Therapeutics Inc.'s stock advanced 1.92%, to close the day at $3.19. The stock recorded a trading volume of 44,597 shares. Cesca Therapeutics' shares have surged 11.93% in the previous one month and 678.05% in the past one year. Shares of the Company, which focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine in the US and internationally, are trading 3.79% and 1.69% below its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 51.02. Get free access to your research report on KOOL at:
http://stock-callers.com/registration/?symbol=KOOL
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
